Dr. Danai Dima, MD
Hematology & Oncology (Hematology & Oncology Physician)
825 Eastlake Ave E
Seattle, WA 98109
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 9
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 28
Licensed in Washington since 2024, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD61556046 (first issued 2024; active) -
Internal Medicine Physician
WA license MD61556046 (first issued 2024; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 28
- Services billed
- 85
- Patients’ average age
- 71
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 11 companies reported 21 payments worth $4,139 in total to this clinician.
| Kite Pharma, Inc. | $2,829 |
|---|---|
| Karyopharm Therapeutics Inc. | $337 |
| Janssen Biotech, Inc. | $241 |
| Novartis Pharmaceuticals Corporation | $137 |
| Stemline Therapeutics Inc. | $117 |
| Legend Biotech USA Inc. | $116 |
| Janssen Scientific Affairs, LLC | $101 |
| Pfizer Inc. | $96.60 |
| Consulting Fee | $2,777 |
|---|---|
| Food and Beverage | $1,353 |
| Travel and Lodging | $8.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. Dec 11, 2025 | Consulting FeeCompany’s description;4283851;GTF;13226550 | $2,640 |
| Karyopharm Therapeutics Inc. Feb 28, 2025 | Consulting Fee XPOVIO · Oncology | $137 |
| Janssen Scientific Affairs, LLC Jul 8, 2025 | Travel and Lodging CARVYKTI · Oncology · travel to Seattle, WA · in-kind | $8.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $270,971 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexam…
Janssen Research & Development, LLC - A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie Inc. · Recruiting · NCT05650632 - A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexam…
Janssen Research & Development, LLC - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
AbbVie Inc. · Recruiting · NCT06158854 - A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion
AbbVie Inc. - A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Janssen Research & Development, LLC - A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - A phase 1B openlabel study of elranatamab in combination with iberdomide in participants with relapsed refractory multiple myeloma
Pfizer Inc. - A Multiarm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 3, Double Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL 101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment Naive Patients with Stage IIIb AL Cardi…
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.